6. Novartis - Top 15 R&D Budgets

Who: Novartis

Based: Switzerland

2006 Pipeline Budget: $5.94 billion (€4.06B)

2007 Pipeline News: In 2007 Novartis gained FDA approval of in the U.S. and EU for Aclasta/Reclast, which is expected to generate $1.2 billion in sales by 2011, and Tekturna, an potential blockbuster drug for hypertension. However, its painkiller Prexige got a "not approvable" letter due to safety concerns, and diabetes drug Galvus has been stalled in the U.S. for similar reasons.

Novartis placed an emphasis on vaccines in 2007, paying Intercell €270 million to license more than 10 early and pre-clinical development programs. The company currently has 138 projects in development, 50 of which are in Phase II or III testing.

Pipeline breakdown*:
Galvus - Diabetes
Xolair - Allergic Asthma

Anticipated 2008 filings:
QAB149 - COPD
LBH589 - Solid tumors
AGO178 - Depression
Tifacogin - CAP
MFF258 - COPD/Asthma
RAD001 - Solid tumors
Tobramycin - Cystic Fibrosis
Tekturna - Hypertension

Anticipated 2009 filings:
LIC477 (US) - Bipolar disorder
FTY720 - Multiple sclerosis
SOM230 - Cushings / GEP3 tumors
EPO906 - Solid tumors
ACZ885 - Muckle Wells
ABF656 - Hepatitis C
Tasigna - GIST
MycograbTM (US) - Severe fungal infections
Galvus - Diabetes

Company Pipeline Site: Link

* Data on the phases of these drugs was not available. The company's pipeline report was broken down according to the anticipated filing date rather than the phase of study.

6. Novartis - Top 15 R&D Budgets
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.